Zymeworks (NASDAQ:ZYME) to Buy Back $200 million in Stock

Zymeworks logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Zymeworks’ board authorized a $200 million share buyback, allowing the company to repurchase up to 10.9% of its outstanding shares through open-market purchases.
  • Analyst sentiment is mostly positive: 12 analysts rate the stock Buy, one Hold, and one Sell, with a consensus “Moderate Buy” rating and a $43.25 price target.
  • The company reported quarterly EPS of $2.28, slightly above estimates, and revenue of $512.92 million versus expectations of $227.40 million.
  • Interested in Zymeworks? Here are five stocks we like better.

Zymeworks (NASDAQ:ZYME - Get Free Report) announced that its board has approved a share buyback plan on Monday, November 16th, RTT News reports. The company plans to repurchase $200 million in outstanding shares. This buyback authorization permits the company to repurchase up to 10.9% of its shares through open market purchases. Share buyback plans are typically an indication that the company's board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on ZYME shares. Wolfe Research assumed coverage on Zymeworks in a research report on Thursday, September 17th. They issued an "outperform" rating for the company. Citigroup increased their price target on Zymeworks from $39.00 to $44.00 and gave the company a "buy" rating in a research note on Wednesday, November 11th. Deutsche Bank set a $32.00 price target on Zymeworks in a research note on Wednesday, August 26th. HC Wainwright raised their price target on Zymeworks from $55.00 to $56.00 and gave the stock a "buy" rating in a report on Tuesday, November 10th. Finally, Stifel Nicolaus set a $46.00 price target on Zymeworks in a research note on Friday, August 7th. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $43.25.

Check Out Our Latest Stock Report on Zymeworks

Zymeworks Price Performance

ZYME traded up $0.21 during trading on Monday, reaching $26.45. 905,093 shares of the company's stock were exchanged, compared to its average volume of 1,376,009. Zymeworks has a 1 year low of $21.52 and a 1 year high of $31.97. The stock has a market capitalization of $1.83 billion, a P/E ratio of 50.87 and a beta of 1.32. The company's fifty day simple moving average is $27.26 and its 200-day simple moving average is $25.50.

Zymeworks (NASDAQ:ZYME - Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported $2.28 EPS for the quarter, beating the consensus estimate of $2.27 by $0.01. The business had revenue of $512.92 million during the quarter, compared to analysts' expectations of $227.40 million. Zymeworks had a net margin of 16.10% and a return on equity of 22.23%. The business's quarterly revenue was up 828.7% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.26) EPS. Equities analysts forecast that Zymeworks will post 1.31 EPS for the current year.

Insider Buying and Selling at Zymeworks

In other Zymeworks news, insider Paul Moore sold 39,741 shares of the company's stock in a transaction on Friday, November 13th. The shares were sold at an average price of $26.07, for a total value of $1,036,047.87. Following the sale, the insider directly owned 33,756 shares of the company's stock, valued at approximately $880,018.92. This represents a 54.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Adam Schayowitz sold 13,832 shares of the company's stock in a transaction on Friday, October 9th. The shares were sold at an average price of $25.85, for a total transaction of $357,557.20. Following the completion of the sale, the executive vice president directly owned 23,205 shares in the company, valued at approximately $599,849.25. The trade was a 37.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 37.73% of the company's stock.

About Zymeworks

(Get Free Report)

Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company's lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Zymeworks Right Now?

Before you consider Zymeworks, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zymeworks wasn't on the list.

While Zymeworks currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines